ArticleJournal of biophotonics2021
Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells.
Article in Journal of biophotonics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07610967 (Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
Who cites it
12 citing papers in PubMed.
- A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting.Clinical and translational science · 2022Trial
- Article
- The inhibitory and inactivating effects of visible light on SARS-CoV-2: A narrative update.Journal of photochemistry and photobiology · 2023Article
- Operative Protocol for Testing the Efficacy of Nasal Filters in Preventing Airborne Transmission of SARS-CoV-2.International journal of environmental research and public health · 2022Article
- Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2.Journal of dentistry · 2022Article
- Whole-organ transdermal photobiomodulation (PBM) of COVID-19: A 50-patient case study.Journal of biophotonics · 2022Article
- Blue Laser Light Counteracts HSV-1 in the SH-SY5Y Neuronal Cell Model of Infection.Life (Basel, Switzerland) · 2022Article
- Antimicrobial blue light: A 'Magic Bullet' for the 21st century and beyond?Advanced drug delivery reviews · 2022Review
- Evaluation of Residual Infectivity after SARS-CoV-2 Aerosol Transmission in a Controlled Laboratory Setting.International journal of environmental research and public health · 2021Article
- Sunlight Exposure and Phototherapy: Perspectives for Healthy Aging in an Era of COVID-19.International journal of environmental research and public health · 2021Review
- Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.International journal of molecular sciences · 2021Review
- Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells.Journal of biophotonics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The study of any intervention able to counteract SARS-CoV-2 pandemic is considerably envisaged. It was previously shown, in in vitro models of infections, that the LED blue light is able to decrease the viral load of HSV-1 and ZIKV. In our study, LED photobiomodulation therapy (PBMT) at blue wavelengths (450, 454 and 470 nm) was tested in an in vitro model of SARS-CoV-2 infection, employing three experimental settings: SARS-CoV-2 was irradiated and then transferred to cells; already infected cells were irradiated; cells were irradiated prior to infection. A decrement of the viral load was observed when previously infected cells were irradiated with all three tested wavelengths and relevant effects were registered especially at 48 hours post-infection, possibly suggesting that the blue light could interfere with the intracellular viral replication machinery. Our in vitro findings could represent the starting point for translational applications of PBMT as a supportive approach to fight SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.